文献速递免疫规划卫生政策与健康促进

澳大利亚老年人接种13价肺炎球菌结合疫苗(PCV13)的成本效果

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
PubMed 文献 · Vaccine · 2017-07-08

本研究用单队列确定性多状态马尔可夫模型,从医疗系统视角评估澳大利亚65岁人群以PCV13替代PPV23的成本效果。结果显示,与不接种相比PCV13的增量成本效果比约A$88,100/质量调整生命年,需降价至约A$46/剂以下才低于A$60,000/质量调整生命年的阈值;与PPV23相比PCV13的增量成本效果比约A$35,300/质量调整生命年,具有成本效果。

要点

  • 与不接种相比,PCV13在65岁人群的增量成本效果比约A$88,100/质量调整生命年,PPV23约A$297,200/质量调整生命年。
  • PCV13要低于A$60,000/质量调整生命年的成本效果阈值,单价需降至约A$46/剂以下。
  • 与PPV23相比,PCV13的增量成本效果比约A$35,300/质量调整生命年,具有成本效果。

核心结论

  • 与不接种相比,65岁人群使用PCV13除非疫苗价格低于A$46或能确立更长的保护持续时间,否则不太可能具有成本效果。
  • 与PPV23相比,接种PCV13具有成本效果,部分反映澳大利亚使用PPV23被估计为资金价值较差。

研究设计与样本

  • 研究采用单队列确定性多状态(马尔可夫)模型,描述人群在不同侵袭性和非侵袭性肺炎球菌疾病相关健康状态间的转移。
  • 研究采用医疗系统视角,成本以澳元(A$)计、健康效果以质量调整生命年(QALY)计,均按每年5%贴现。
  • 研究探索在65岁以PCV13替代PPV23以及其他基于年龄的接种策略,并用确定性和概率敏感性分析探索参数不确定性。

主要发现

  • 在单队列中,估计65岁接种PCV13花费约A$11,120,000,预防侵袭性肺炎球菌病39例住院和6例死亡,以及社区获得性肺炎180例住院和10例死亡。
  • 与不接种相比,PCV13项目的增量成本效果比约A$88,100/QALY gained,PPV23约A$297,200/QALY gained。
  • PCV13要低于A$60,000/QALY的成本效果阈值,价格须低于约A$46/剂。
  • 与PPV23相比,PCV13的成本效果约A$35,300/QALY gained。

关键数值与推荐

  • 成本效果阈值为A$60,000/QALY。
  • PCV13与不接种相比增量成本效果比约A$88,100/QALY gained,PPV23约A$297,200/QALY gained。
  • PCV13与PPV23相比增量成本效果比约A$35,300/QALY gained。
  • PCV13价格须低于约A$46/剂才低于A$60,000/QALY阈值。

临床怎么用

  • 作者认为,与不接种相比,65岁人群使用PCV13除非价格低于A$46或能确立更长保护持续时间,否则不太可能具有成本效果。
  • 作者认为,与PPV23相比,接种PCV13具有成本效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 23-valent pneumococcal polysaccharide vaccine (PPV23) has been funded under the Australia National Immunisation Program (NIP) since January 2005 for those aged >65years and other risk groups. In 2016, PCV13 was accepted by the Pharmaceutical Benefits Advisory Committee (PBAC) as a replacement for a single dose of PPV23 in older Australian adults. METHODS: A single-cohort deterministic multi-compartment (Markov) model was developed describing the transition of the population between different invasive and non-invasive pneumococcal disease related health states. We applied a healthcare system perspective with costs (Australian dollars, A$) and health effects (measured in quality adjusted life-years, QALYs) attached to model states and discounted at 5% annually. We explored replacement of PPV23 with PCV13 at 65years as well as other age based vaccination strategies. Parameter uncertainty was explored using deterministic and probabilistic sensitivity analysis. RESULTS: In a single cohort, we estimated PCV13 vaccination at the age of 65years to cost ∼A$11,120,000 and prevent 39 hospitalisations and 6 deaths from invasive pneumococcal disease and 180 hospitalisations and 10 deaths from community acquired pneumonia. The PCV13 program had an incremental cost-effectiveness ratio of ∼A$88,100 per QALY gained when compared to a no-vaccination, whereas PPV23 was ∼A$297,200 per QALY gained. To fall under a cost-effectiveness threshold of A$60,000 per QALY, PCV13 would have to be priced below ∼A$46 per dose. The cost-effectiveness of PCV13 in comparison to PPV23 was ∼A$35,300 per QALY gained. CONCLUSION: In comparison to no-vaccination, we found PCV13 use in those aged 65years was unlikely to be cost-effective unless the vaccine price was below A$46 or a longer duration of protection can be established. However, we found that in comparison to the PPV23, vaccination with PCV13 was cost-effective. This partly reflects the poor value for money estimated for PPV23 use in Australia.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Dirmesropian S, Wood JG, MacIntyre CR, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians. Vaccine. 2017. PMID: 28693751. doi:10.1016/j.vaccine.2017.06.085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。